Evaluation of blood rheology indices in patients with pheochromocytoma;Ocena wskaźników reologicznych krwi u chorych z pheochromocytoma

Polskie Archiwum Medycyny Wewnetrznej

Volumn 95, Issue 3, 1996, Pages 190-197

  Berent, Hanna ^a   Wocial, Bozenna ^a   Kuczyńska, Krystyna ^a   Kochmański, Marek ^a   Ignatowska Świtalska, Hanna ^a   Januszewicz, Andrzej ^a   ŁApińSki, Mariusz ^a   Andowski, Jacek Lew ^a   Januszewicz, WŁodzimierz ^a  

^a NONE

Author keywords

Blood platelets; Blood rheology; Pheochromocytoma

Indexed keywords

BETA THROMBOGLOBULIN; FIBRINOGEN; NEUROPEPTIDE Y;

ADRENERGIC SYSTEM; ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERYTHROCYTE DEFORMABILITY; FEMALE; FLOW KINETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHEOCHROMOCYTOMA;

ADULT; BETA-THROMBOGLOBULIN; ERYTHROCYTE DEFORMABILITY; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; NEUROPEPTIDE Y; PHEOCHROMOCYTOMA; RHEOLOGY; SYMPATHETIC NERVOUS SYSTEM;

EID: 2842590332     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Anderton J.L., Fananapazir L., Dawes I., i wsp. Urinary B-thromboglobulin in essential hypertension. Brit. J. Haematol., 1980, 44, 307.
2. Berent H. Kochmański M., Kuczyńska K. i wsp.: Rola czynników reologicznych w patogenezie nadciśnienia tȩtniczego. Kardiol. Pol., 1995, 42, 463.
3. Berent H. Kuczyńska K.: Niektóre aspektey czynności krwinek plytkowych w nadciśnieniu tȩtniczym. Pol. Tyg. Lek., 1989, 44, 30.
4. Buhler F. R., Amstein R., Fetkovska N.: Serotonin and preactivated platelets in essential hypertension. J. Cardiovasc. Pharmacol., 1987, 10, 3, 32.
5. 2+ concentration in essential hypertension. Hypertension, 1992, 19, 167.
6. De Clerck F.: Blood platelets in human essential hypertension. Agents and Actions, 1986, 18, 563.
7. Dintenfass L.: Blood viscosity, hyperviscosity and hyperviscosaemia. MPT Press Ltd, Lancastes-Boston-The Hugue-Dordrecht, 1985.
8. Di Perri T.: Rheological factors in circulatory disorders. Angiology, 1979, 30, 480.
9. Dormandy J. A., Yates C.J.P., Berent G. A.: Clinical relevance of blood viscosity and red cell deformability including newer therapeutic aspects. Angiology, 1981, 32, 236.
10. Ernst E., Welhmayr T., Schmidt M. i wsp.: Cardiovascular risk factors and hemorheology. Physical fitness, stress and obesity. Atherosclerosis, 1986, 59, 163.
11. Fogari R., Zoppi A. Marasi G.i wsp.: Associations between plasma fibrinogen levels and cardiovascular risk factors in hypertensive men. J. Cardiovasc. Risc, 1994, 1, 341.
12. 2+ - ATPase activity in children with and without family history of essential hypertension. J. Human Hypertens., 1990, 4, 147.
13. Kjeldsen S.E., Gjesdal K., Kide I.: Increased beta-thromboglobulin in essential hypertension: interactions between arterial plasma adrenaline, platelet funtion and blood lipids. Acta Med. Scand, 1983, 213, 369.
14. Koenig W., Sund M., Ernsts E. et al.: Association between plasma viscosity and blood pressure. Results from the MONICA - Project Augsburg. Am. J. Hypertens., 1991, 4, 429.
15. Lip G. Y. H., Beevers D.G.: Abnormalities of rheology and coagulation in hypertension. J. Human Hypertens., 1994, 8, 693.
16. Longhini E., Agosti R., Cherubim P. et al.: Haemoreology in hypertension. Clin. Haemoreol., 1986, 6, 567.
17. Lundberg J.M. Hemsen A.: Neuropeptide Y receptors in pig spleen: binding characteristic, reduction of cyclic AMP formation and calcium antagonists inhibition of vasoconstriction. Eur. J. Pharmacol. 1988, 145, 21
18. Lyusov V.A., Dudaev V.A., Mubarak M. i wsp. Blood rheologic properties in hypertensive patients. Kardiologia, 1986, 26, 70.
19. Manger W.M., Gifford R. W., Hoffman B.B.: Pheochromocytoma a clinical and experimental overview. Curr. Probl. Cancer, 1985, 5, 1.
20. Petralito A. Fiore C.E., Mangiafice R.A : B-thromboglobulin plasma levels in different stages of arterial hypertension. Thromb. Hacmostas. (Stuttgart), 1982, 48, 241.
21. + exchange in patients with essential hypertension. Am. J. Hypertens, 1989, 2, 903.
22. Smith E.B., Keeng G., Grant A. i wsp.: Fate of fibrinogen in human arterial intima. Arteriosclerosis, 1990, 10, 263.
23. Westlind- Danielsson A., Andell S.: Neuropeptide Y and peptide YY inhibit cycclase activity in the rat stratium. Acta Physiol. Scand., 1988, 14, 263.
24. Wójcicki J.: Fibrynogen jest ważnym czynnikiem zagrożenia miażdżyca̧. Czynniki ryzyka 1995, 2, 21.
25. Vlachakis N.D., Aledort L.: Platelet aggregation relationship to plasma catecholamines in patients with hypertension. Atherosclerosis, 1979, 32, 451.
26. Vlachakis N.D.: Hypertension and propranolol therapy: effect on blood pressure, plasma catecholamines and platelet aggregation. Amer. J. Cardiol., 1980, 45, 32.
27. Zannad F. Voisin P., Brunotte F. i wsp.: Haemorheological abnormalities in arterial hypertension and their relation to cardiac hypertrophy. J. Hypertension, 1988, 6, 293.